Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

Recombinant Glycoprotein Vaccine for the Prevention of Genital


Journal of the American Medical Association (07/28/99) Vol.

Investigators for the Chiron HSV Vaccine Study Group found that protection from herpes simplex virus type 2 (HSV-2) will require vaccines to do more than induce high levels of specific neutralizing antibodies. The researchers conducted two randomized, double-blind, placebo-controlled multicenter trials of a recombinant subunit vaccine against the virus. The vaccine contained gB2 and gD2, HSV-2 surface proteins against which neutralizing antibodies are directed. Subjects were vaccinated at months 0, 1, and 6. Participants in the control group received a citrate buffer vehicle, and all subjects were followed up after the third immunization. Researchers measured outcome by time to acquisition of HSV-2. During the first five months of the trial, those receiving the vaccine had a 50 percent lower acquisition rate than the controls. According to the data, the acquisition rate of HSV- 2 for vaccinated subjects was 4.6 per 100 patient years, compared to 4.2 per 100 patients years in those receiving the placebo. Although the vaccine induced high levels of HSV-2 specific neutralizing antibodies in all subjects, follow-up study revealed that the vaccine had no significant influence on duration of clinical first episodes of genital HSV-2 or frequency of reactivation. Furthermore, overall vaccine efficacy was 9 percent. The researchers assert that an effective vaccine must have a higher efficacy level than 9 percent and should do more than stimulate high levels of specific neutralizing antibodies.


Copyright © 1999 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

Information in this article was accurate in July 28, 1999. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.